EP1960412A2 - Sel d'amphotéricine b - Google Patents

Sel d'amphotéricine b

Info

Publication number
EP1960412A2
EP1960412A2 EP06820400A EP06820400A EP1960412A2 EP 1960412 A2 EP1960412 A2 EP 1960412A2 EP 06820400 A EP06820400 A EP 06820400A EP 06820400 A EP06820400 A EP 06820400A EP 1960412 A2 EP1960412 A2 EP 1960412A2
Authority
EP
European Patent Office
Prior art keywords
amphotericin
meglumine
salt
molar ratio
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06820400A
Other languages
German (de)
English (en)
Inventor
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drug Discovery Laboratory AS
Original Assignee
Drug Discovery Laboratory AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drug Discovery Laboratory AS filed Critical Drug Discovery Laboratory AS
Publication of EP1960412A2 publication Critical patent/EP1960412A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to a salt of amphotericin B and meglumine, pharmaceutical compositions containing said salt and methods of treatment using said salt.
  • Amphotericin B also known as fungizone, is a macrolide polyene antibiotic produced by Streptomycetes nodosus M4575 having a formula C 47 H 73 NOi 7 and the molecular weight 924 Da. It is insoluble in water except at strongly acid or base pH values and even then has a solubility of about 0.1 mg/mL.
  • Candida Cr ⁇ ptococcus
  • Aspergillus Aspergillus
  • Ajellomyces Fusarium
  • Coccidiodes Fusarium
  • Leishmania Schistosomia
  • Torulopsis Giardia
  • Giardia Trichomonas
  • Entamoeba species fungal activity
  • amphotericin B is generally administered as a colloidal formulation, e.g. as a complex with cholesteryl sulphate, or in a lipid or liposomal formulation.
  • a colloidal formulation e.g. as a complex with cholesteryl sulphate
  • injection of the liposomal or lipid formulation is the preferred treatment for the developing world disease leishmaniasis, which affects an estimated 1.5 million new victims per year globally, and is referred to for example by Sundar et al Annals of Internal Medicine 127:133-137(1997).
  • Such formulations may however cost 10 to 30 times the simple colloidal formulation and in practice are thus inaccessible to the majority of potential patients.
  • Meglumine N-methylglucamine
  • Meglumine N-methylglucamine
  • MR.imaging e.g. Magnevist® from Schering AG
  • the invention provides a salt of amphotericin B and meglumine in which the molar ratio of amphotericin B to meglumine is about 1 : 1 (e.g. 1:1 to 1:1.1).
  • Amphotericin B meglumate has a mole ratio of 1 : 1 ; however, it may be presented with a slight excess of meglumine, or less advantageously a slight excess of amphotericin B.
  • the salt of the invention has an activity (ED/mg) against Candida albicans of from 500 to 650, especially 550 to 620, as opposed to the value of 750 for amphoglucamine.
  • the salt of the invention forms significantly less alkaline aqueous solutions than does amphoglucamine, e.g. at a concentration of 50mg amphotericin B/mL in water at 25 0 C, the pH is below 9.0, typically about 8.6, as opposed to the value of 9.3 for amphoglucamine. This makes the salt more suitable for parenteral injection than amphoglucamine.
  • the invention provides a composition of matter consisting essentially of a salt of amphotericin B and meglumine in which the molar ratio of amphotericin B to meglumine is about 1 : 1 (e.g. 1 : 1 to 1 : 1 , 1).
  • an injectable pharmaceutical composition comprising an aqueous solution containing dissolved therein amphotericin B and meglumine, or ions thereof, in a molar ratio of about 1 : 1 (e.g. 1:1 to 1:1.1).
  • the invention provides the use of a salt of amphotericin B and meglumine in which the molar ratio of amphotericin B to meglumine is about 1:1 (e.g. 1 :1 to 1:1.1) for the manufacture of an injectable medicament for use in the treatment by parenteral injection of systemic fungal infection or other systemic infections responsive to amphotericin B.
  • the invention provides a method of treatment of a human or non-human mammalian subject having a systemic infection responsive to amphotericin B (e.g. a fungal or protozoal infection) which method comprises parenterally injecting said subject with an effective amount of an aqueous solution containing dissolved therein amphotericin B and meglumine, or ions thereof, in a molar ratio of about 1 :1 (e.g. 1:1 to 1:1.1).
  • amphotericin B e.g. a fungal or protozoal infection
  • the injection solution used in the method of the invention should be sterile and preferably pyrogen- free and may be prepared using the salt in sterile form, a form which is preferred.
  • the solution may if desired contain further components beyond water and the amphotericin B meglumate complex, e.g. physiologically tolerable osmolality adjusting agents (for example to render the solution isotonic, such as sodium chloride for example), preservatives, buffers, further active agents, etc.
  • the solutions may contain up to 0.9% wt. of sodium chloride as an osmolality adjuster.
  • the injection solution according to the present invention is preferably isotonic.
  • a solution of amphoglucamine is always hypertonic if the concentration of amphotericin is above 60 to 70 mg per ml (calculated as the 1 :1 salt with meglumine) based on the fact that this complex contains 3 moles excess of meglumine.
  • the present 1 :1 salt can be formulated as an isotonic solution in concentrations up to 150 mg per ml, and is preferably presented in such a solution at an amphotericin B concentration of 90 to 140 mg/mL.
  • amphotericin B: meglumine salt of and used according to the present invention is not identical to amphoglucamine which, as discussed above, contains amphotericin B and meglumine in a mole ratio of less than 1:3.
  • the amphoglucamine product is hygroscopic while the amphotericin B meglumate salt of the present invention is not hygroscopic.
  • the amphoglucamine is, as it is described in the prior art, a complex with an undefined excess of meglumine.
  • a product with an undefined amount of a compontent like in amphoglucamine is not a well-defined product as the 1 :1 salt is , from a regulatory point of view.
  • the use of amphoglucamine in aqueous solution for parenteral injection has not been proposed.
  • the aqueous solutions of the salt used according to the invention will typically contain the salt at a concentration of 0.5 to 150 mg/mL, preferably 1 to 120 mg/mL, especially 50 to 80 mg/mL. Doses of up to 50 mg amphotericin B for an adult human are preferred. These compositions may be administered at amphotericin B dosages typical for the current lipid or liposomal formulations of amphotericin B, e.g. 0.1 to 8 mg/kg bodyweight/day, preferably 1 to 5 mg/kg/day. The treatment may typically be carried out for up to 80 days.
  • the salt according to the invention may if desired be stabilized by autoclaving. It is thought that the salt is more stable to exposure to autoclaving temperatures than the prior art amphoglucamine complex.
  • Administration maybe by infusion or routine injection, e.g. bolus injection, for example intravascular, intramuscular, or subcutaneous. Infusion, e.g. over 1 to 2 hours, is preferred.
  • the amphotericin B megluminate salt according to the invention may be prepared in solution in solvents such as DMSO, DMF, N-methylpyrrolidone (NMP) and/or alcohols (e.g. Ci -6 alkanols such as methanol) or mixtures thereof.
  • solvents such as DMSO, DMF, N-methylpyrrolidone (NMP) and/or alcohols (e.g. Ci -6 alkanols such as methanol) or mixtures thereof.
  • NMP and/or alcohols is especially preferred as extensive work-up to remove solvents such as DMSO or DMF is avoided.
  • the reaction is effected by using approximately equimolar amounts of amphotericin B and meglumine.
  • the salt can be recovered by addition of an ether (e.g. diethyl ether) or a ketone (e.g.
  • the invention provides a process for the preparation of a salt of amphotericin B and meglumine which comprises mixing amphotericin B and meglumine in solution in a solvent in approximately equimolar amounts, e.g. a molar ratio of 1 :1 to 1 :1.1, followed by solvent removal or precipitation.
  • the resultant salt is substantially non-hygroscopic, unlike amphoglucamine.
  • Hygroscopisity of freeze-dried Amphotericin B meglumate Amphotericin B meglumate (16.4 mg) (from Example 1) was kept open in a vial at room temperature (23-24°C) and ambient humidity (34-38%) in the dark for several days. The sample did not gain any appreciable weight. The product was not hygroscopic.
  • Aqueous solutions of amphotericin B meglumate (5 mg/mL) were kept at room temperature and at 4O 0 C for 11 days in the dark. No sign of degradation was observed in these samples (visual inspection and HPLC analysis).
  • composition 350 mg Amphotericin B meglumate (1:1) (produced according to Example 1) is dissolved in 70 mL water for injections and filled under sterile conditions into a vial which is then sealed.
  • MIC values ⁇ Candida albicans) and ⁇ Candida kruse ⁇ ) for amphotericin B meglumate and amphotericin B in water and DMSO was determined in vitro using standard methods.
  • Example 8 pH in aqeuous solution of Amphotericin B meglumate (1:1) Amphotericin B meglumate (prepared in Example 7) was dissolved in water ( 50 mg amphotericin per ml). The pH of the solution at 25 0 C was 8.6.
  • Amphotericin meglumine complex (1 :3) was prepared according to US 4,002,741. The complex was dissolved in water (50 mg amphotericin B per ml). The pH in the solution was 9.3 at 25°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne un sel d'amphotéricine B et de méglumine dans lequel le rapport molaire entre l'amphotéricine B et la méglumine est d'environ 1:1.
EP06820400A 2005-12-02 2006-12-04 Sel d'amphotéricine b Withdrawn EP1960412A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0524685.5A GB0524685D0 (en) 2005-12-02 2005-12-02 Compound
PCT/GB2006/004514 WO2007063335A2 (fr) 2005-12-02 2006-12-04 Sel d'amphotéricine b

Publications (1)

Publication Number Publication Date
EP1960412A2 true EP1960412A2 (fr) 2008-08-27

Family

ID=35686013

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06820400A Withdrawn EP1960412A2 (fr) 2005-12-02 2006-12-04 Sel d'amphotéricine b

Country Status (3)

Country Link
EP (1) EP1960412A2 (fr)
GB (1) GB0524685D0 (fr)
WO (1) WO2007063335A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2606781T3 (es) 2010-07-23 2017-03-27 Acea Biotech, Inc. Macrólidos polienos antifúngicos y antiparasitarios
DE102014012022A1 (de) * 2014-08-13 2016-02-18 Clariant International Ltd. Organische Ammoniumsalze von anionischen Pestiziden

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002741A (en) * 1974-04-24 1977-01-11 Valter Osvaldovich Kulbakh Meglumine complex fungicidal polyene macrolide antibiotic compositions and treatment method
GB1430886A (en) * 1974-05-01 1976-04-07 Le Nii Antibiotikov Meglumine compolexes of fungicidal polyene antibiotics-macrolides
US5942495A (en) * 1996-05-10 1999-08-24 Btg International Limited Antibiotics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007063335A2 *

Also Published As

Publication number Publication date
GB0524685D0 (en) 2006-01-11
WO2007063335A3 (fr) 2007-09-20
WO2007063335A2 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
HU176215B (en) Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
EP0474874A1 (fr) Compositions d'inhibiteur de la reaction de Maillard
CZ292423B6 (cs) Krystalický, bezvodý mykofenolát mofetilu a intravenózní prostředek, ve kterém je obsažen
EP2982669B1 (fr) Agents chelatants d'ions metalliques, leurs procedes de preparation et leurs applications
EP2620153B1 (fr) Injection de 5 alpha-androstane-(alkyl)-3 beta,5,6 beta-triol et son procédé de préparation
EP1132395B1 (fr) Procédé pour la préparation d'un peptide pharmacologiquement actif
WO2007063335A2 (fr) Sel d'amphotéricine b
DE69818823T2 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
CA3169260A1 (fr) Compositions pharmaceutiques comprenant de l'acetate de 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl] et des ions sodium
FR2796551A1 (fr) Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US4144328A (en) N,N,N-Trimethyl derivatives of polyene amphoteric antibiotics, process of producing same and pharmaceutical composition
PT90301B (pt) Processo para a preparacao de novos derivados 6-fosfono-alquilicos de purina e de composicoes farmaceuticas que os contem
SU1428208A3 (ru) Способ получени комплексов полиеновый антибиотик - @ -циклодекстрин
JPH11504647A (ja) 抗生物質
DE3503614A1 (de) All-cis-1,3,5-triamino-2,4,6-cyclohexantriol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate
AU772277B2 (en) Diphosphate salt of a 4''-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition
EP1696935B1 (fr) Nouveaux derives de la morphine-6-glucuronide, compositions pharmaceutiques les contenant, leur procede de preparation et leurs utilisations
US7550628B2 (en) Process for preparing phenolic acid salts of gabapentin
EP1140197B1 (fr) Compositions solubles de toremifene
KR101435244B1 (ko) 목시플록사신 수성 제형 및 이의 제조방법
US3461211A (en) Lipotropic compositions and their administration
US20070021359A1 (en) Addition salts of azithromycin and citric acid and process for preparing them
CA2876454A1 (fr) Esters de bortezomib et formulations de ceux-ci
KR20090008512A (ko) 세포테탄 이나트륨염의 신규 제조방법
JP4338517B2 (ja) グアニジン誘導体の塩及び該塩から成る製薬学的調剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080630

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20081107

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090519